This Life Saving Science is About To Make Investors a Fortune

The regenerative medicine future is nearly upon us.

We’ve made great strides in stem cell research, using them to replace damaged tissues in the body. It will be transformative.

In labs across the country, as I write this, organs are growing in small petri dishes. Once this science is refined, it will change the way the medical community treats your ailments.

But the current state of the technology hasn’t happened overnight. It’s been decades since the potential for stem cell technology captured the public imagination.

Myself, I’ve spent the past 10 years researching the profit potential of regenerative medicine.

I’ve traveled all over the country, attended scientific conferences, visited research laboratories and spoken to experts in the field for hours on end. It’s been fascinating watching things unfold.

I even banked my children’s umbilical cord blood at birth. It’s rich in stem cells and could one day save their lives. It’s cryogenically preserved waiting for a future breakthrough and need.

The pieces of the puzzle are finally starting to come together in such a way that you and I can expect to personally benefit from applications of regenerative medical science — in a big way.

The center of stem cell innovation has long been the United States, and that hasn’t really changed. The big hurdle, however, remains commercializing much of this powerful technology.

Our regulatory framework has been a dinosaur unable to keep up with the fast-paced change in the scientific realm. The FDA wasn’t set up to regulate cell-based therapies like these, many of which will be personalized and customized to suit a specific patient.

That’s starting to change.

The 21st Century Cures Act, which passed Congress and was signed into law late last year, will help modernize the agency. This, in turn, will help speed along commercialization of regenerative medicine.

President’s Trump’s potential FDA nominee will also likely be someone who wants to reform the agency with a favorable leaning toward regenerative and anti-aging therapies.

But there’s another country that has been well ahead of the U.S. in properly regulating the commercialization of cell-based regenerative therapies. That country is Japan.

In 2012, the Nobel Prize in Physiology or Medicine was awarded to stem cell researcher Shinya Yamanaka. Yamanaka had independently discovered a way to take an adult cell, modify its DNA code and return it to a primitive state.

These are ”generic cells”. They are generic in the sense that they can become any other cell type. They are known as induced pluripotent stem (iPS) cells and can be made from any kind of cell, even a skin cell.

Once iPS cells are created, they can, when properly coaxed, turn into any other kind of cell, whether of the heart, muscle or brain.

Anything.

This isn’t science fiction anymore. I’ve seen human skin cells scraped off a subject’s arm and then transformed into iPS cells in the lab… and then transformed again into beating heart cells.

This technology is just waiting to be put to good use in treating human ailments.

The Japanese understand that addressing the age-related health problem is going to take much more than merely treating diseases associated with growing old.

One of the core problems is aging cells. Stem cell science has the power to replace old cells with young ones and bring aging, failing tissues into youthful function again.

This is a science that’s making waves on a global level.

And like most trends in its infancy, it’s the perfect time to profit from companies specializing in regenerative medicine breakthroughs.

The most forward-looking pharmaceutical and biotechnology companies are in an enviable position to bring lifesaving and life-changing therapies to market — earning huge revenues for shareholders.

To a bright future,

Ray Blanco
for The Daily Reckoning

The Daily Reckoning